{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bladder+Biopsy", "query": { "intervention": "Bladder Biopsy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 55, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bladder+Biopsy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T18:20:56.100Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05059444", "title": "ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Carcinoma", "Ureter Carcinoma", "Renal Pelvis Carcinoma", "Non-small Cell Lung Cancer", "Invasive Breast Carcinoma", "Cutaneous Melanoma", "Esophageal Carcinoma", "Gastroesophageal Junction Carcinoma", "Gastric Adenocarcinoma", "Pancreatic Adenocarcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Epithelial Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Endometrial Carcinoma", "Renal Cell Carcinoma", "Rectal Adenocarcinoma" ], "interventions": [ { "name": "Guardant Reveal", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Guardant Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2020, "start_date": "2021-09-07", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-09-08T18:20:56.100Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05059444" }, { "nct_id": "NCT07288112", "title": "DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Melanoma" ], "interventions": [ { "name": "DOC1021", "type": "BIOLOGICAL" }, { "name": "Tumor resection", "type": "PROCEDURE" }, { "name": "pIFN (peginterferon alfa-2a)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Diakonos Oncology Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2026-04-06", "completion_date": "2033-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-08T18:20:56.100Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288112" }, { "nct_id": "NCT03258658", "title": "Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urologic Diseases", "Male Urogenital Diseases", "Urethral Stricture", "Urethral Injury" ], "interventions": [ { "name": "Autologous Engineered Urethral Construct", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "21 Years to 75 Years · Male only" }, "enrollment_count": 10, "start_date": "2027-01", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-08T18:20:56.100Z", "location_count": 2, "location_summary": "San Francisco, California • Winston-Salem, North Carolina", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03258658" }, { "nct_id": "NCT05054790", "title": "Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Contracted Bladder" ], "interventions": [ { "name": "\"Neo-Bladder\" Construct", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 10, "start_date": "2027-12", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-08T18:20:56.100Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05054790" }, { "nct_id": "NCT00615043", "title": "Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Disease" ], "interventions": [ { "name": "Bladder biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Tengion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 6, "start_date": "2008-02", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2010-12-22", "last_synced_at": "2026-09-08T18:20:56.100Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00615043" }, { "nct_id": "NCT00577785", "title": "Study to Obtain Full Thickness Bladder Tissue From Subjects Undergoing Cystectomy Surgery", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystectomy" ], "interventions": [ { "name": "tissue procurement", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Tengion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 52, "start_date": "2007-08", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2010-12-22", "last_synced_at": "2026-09-08T18:20:56.100Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577785" }, { "nct_id": "NCT00777491", "title": "Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "induction cisplatin", "type": "DRUG" }, { "name": "induction 5-fluorouracil", "type": "DRUG" }, { "name": "induction gemcitabine", "type": "DRUG" }, { "name": "Induction BID radiation therapy", "type": "RADIATION" }, { "name": "Induction QD radiation therapy", "type": "RADIATION" }, { "name": "Consolidation BID radiation therapy", "type": "RADIATION" }, { "name": "Consolidation QD radiation therapy", "type": "RADIATION" }, { "name": "consolidation gemcitabine", "type": "DRUG" }, { "name": "consolidation 5-fluorouracil", "type": "DRUG" }, { "name": "consolidation cisplatin", "type": "DRUG" }, { "name": "radical cystectomy", "type": "PROCEDURE" }, { "name": "Post-Induction Chemoradiotherapy Endoscopic Response Evaluation", "type": "PROCEDURE" }, { "name": "adjuvant gemcitabine", "type": "DRUG" }, { "name": "adjuvant cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 70, "start_date": "2008-12", "completion_date": "2022-05-20", "has_results": true, "last_update_posted_date": "2022-06-15", "last_synced_at": "2026-09-08T18:20:56.100Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Boise, Idaho • Springfield, Illinois + 5 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00777491" }, { "nct_id": "NCT06980038", "title": "Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Nasal Cavity Squamous Cell Carcinoma", "Oral Cavity Squamous Cell Carcinoma", "Oropharyngeal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Nasal Cavity Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Nasopharyngeal Carcinoma AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Lip and Oral Cavity Cancer AJCC v8" ], "interventions": [ { "name": "Anti-CD40 Agonist Monoclonal Antibody CDX-1140", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tumor Resection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2026-05-27", "completion_date": "2027-11-24", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-08T18:20:56.100Z", "location_count": 11, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 7 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06980038" }, { "nct_id": "NCT03258593", "title": "Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Vicineum", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "Bladder Biopsy", "type": "PROCEDURE" }, { "name": "TURBT", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Urine cytology", "type": "DIAGNOSTIC_TEST" }, { "name": "Electrocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-06-07", "completion_date": "2022-10-17", "has_results": true, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-08T18:20:56.100Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03258593" }, { "nct_id": "NCT02463448", "title": "Autologous Muscle Derived Cells for Underactive Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Retention", "Urinary Incontinence" ], "interventions": [ { "name": "Autologous Muscle Derived Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jason Gilleran", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2016-11-16", "completion_date": "2020-11", "has_results": true, "last_update_posted_date": "2022-01-19", "last_synced_at": "2026-09-08T18:20:56.100Z", "location_count": 1, "location_summary": "Royal Oak, Michigan", "locations": [ { "city": "Royal Oak", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02463448" } ] }